These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38447754)

  • 1. Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options-the ICONA Foundation cohort study.
    Lo Caputo S; Poliseno M; Tavelli A; Gagliardini R; Rusconi S; Lapadula G; Antinori A; Francisci D; Sarmati L; Gori A; Spagnuolo V; Ceccherini-Silberstein F; d'Arminio Monforte A; Cozzi-Lepri A;
    Int J Infect Dis; 2024 Jun; 143():106956. PubMed ID: 38447754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes.
    Hsu RK; Fusco JS; Henegar CE; Vannappagari V; Clark A; Brunet L; Lackey PC; Pierone G; Fusco GP
    BMC Infect Dis; 2023 Feb; 23(1):91. PubMed ID: 36782125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.
    Saracino A; Lorenzini P; Lo Caputo S; Girardi E; Castelli F; Bonfanti P; Rusconi S; Caramello P; Abrescia N; Mussini C; Monno L; d'Arminio Monforte A;
    Clin Microbiol Infect; 2016 Mar; 22(3):288.e1-8. PubMed ID: 26551839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort.
    Pelchen-Matthews A; Borges ÁH; Reekie J; Rasmussen LD; Wiese L; Weber J; Pradier C; Degen O; Paredes R; Tau L; Flamholc L; Gottfredsson M; Kowalska J; Jablonowska E; Mozer-Lisewska I; Radoi R; Vasylyev M; Kuznetsova A; Begovac J; Svedhem V; Clark A; Cozzi-Lepri A;
    J Acquir Immune Defic Syndr; 2021 Jun; 87(2):806-817. PubMed ID: 33587506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.
    Gianotti N; Lorenzini P; Cozzi-Lepri A; De Luca A; Madeddu G; Sighinolfi L; Pinnetti C; Santoro C; Meraviglia P; Mussini C; Antinori A; d'Arminio Monforte A;
    J Antimicrob Chemother; 2019 Sep; 74(9):2732-2741. PubMed ID: 31173639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression.
    Gianotti N; Marchetti G; Antinori A; Saracino A; Gori A; Rizzardini G; Lichtner M; Bandera A; Mussini C; Girardi E; dʼArminio Monforte A; Cozzi-Lepri A
    J Acquir Immune Defic Syndr; 2017 Dec; 76(4):417-422. PubMed ID: 28816721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and viral suppression among people living with HIV from the National Free Antiretroviral Therapy Programme, 2019.
    Zhao Y; Han MJ; Gan XM; Ma Y; Zhao DC
    HIV Med; 2020 Dec; 21(11):701-707. PubMed ID: 33369034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.
    Silveira MP; Silveira CP; Guttier MC; Page K; Moreira LB
    J Clin Pharm Ther; 2016 Dec; 41(6):689-694. PubMed ID: 27676134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda.
    Rusine J; Asiimwe-Kateera B; van de Wijgert J; Boer KR; Mukantwali E; Karita E; Gasengayire A; Jurriaans S; de Jong M; Ondoa P
    PLoS One; 2013; 8(8):e64345. PubMed ID: 23950859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options.
    Bajema KL; Nance RM; Delaney JAC; Eaton E; Davy-Mendez T; Karris MY; Moore RD; Eron JJ; Rodriguez B; Mayer KH; Geng E; Garris C; Saag MS; Crane HM; Kitahata MM;
    AIDS; 2020 Nov; 34(14):2051-2059. PubMed ID: 33055569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013.
    d'Arminio Monforte A; Galli L; Lo Caputo S; Lichtner M; Pinnetti C; Bobbio N; Francisci D; Costantini A; Cingolani A; Castelli F; Girardi E; Castagna A;
    J Acquir Immune Defic Syndr; 2014 Nov; 67(3):258-67. PubMed ID: 25314248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suboptimal immune recovery and associated factors among people living with HIV/AIDS on second-line antiretroviral therapy in central China: A retrospective cohort study.
    Zhu K; Xu Q; Ma Y; Li P; Jia H; Jiang Q; Wang Y; Wu Z; Wang D; Guo H; Jin Y
    J Med Virol; 2022 Oct; 94(10):4975-4982. PubMed ID: 35710693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
    Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda.
    Ndahimana Jd; Riedel DJ; Mwumvaneza M; Sebuhoro D; Uwimbabazi JC; Kubwimana M; Mugabo J; Mulindabigwi A; Kirk C; Kanters S; Forrest JI; Jagodzinski LL; Peel SA; Ribakare M; Redfield RR; Nsanzimana S
    Trop Med Int Health; 2016 Jul; 21(7):928-35. PubMed ID: 27125473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
    Phillips AN; Staszewski S; Weber R; Kirk O; Francioli P; Miller V; Vernazza P; Lundgren JD; Ledergerber B; ; ;
    JAMA; 2001 Nov; 286(20):2560-7. PubMed ID: 11722270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.
    Meybeck A; Alidjinou EK; Huleux T; Boucher A; Tetart M; Choisy P; Bocket L; Ajana F; Robineau O
    AIDS Patient Care STDS; 2020 Feb; 34(2):51-58. PubMed ID: 32049556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological and virological discordance among people living with HIV on highly active antiretroviral therapy in Tigray, Northern Ethiopia.
    Hailu GG; Wasihun AG
    BMC Infect Dis; 2021 Jun; 21(1):561. PubMed ID: 34118891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study.
    Lombardi F; Bruzzesi E; Bouba YR; Di Carlo D; Costabile V; Ranzenigo M; Maggiolo F; Castagna A; Callegaro AP; Zoncada A; Paolucci S; Micheli V; Renica S; Bezencheck A; Rossetti B; Santoro MM
    AIDS Res Hum Retroviruses; 2024 Feb; 40(2):80-89. PubMed ID: 37345697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.